Litigation Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (S.D. Fla. 2021)

United Therapeutics Corporation v. Liquidia Technologies, Inc. (S.D. Fla. 2021)

Docket		Date Filed	2021-08-02
Court	District Court, S.D. Florida	Date Terminated	2021-08-17
Cause	35:0271 Patent Infringement	Assigned To	Darrin Phillip Gayles
Jury Demand	None	Referred To
Patents	10,716,793; 9,593,066; 9,604,901
Link to Docket	External link to docket

Details for United Therapeutics Corporation v. Liquidia Technologies, Inc. (S.D. Fla. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-08-02				External link to document

United Therapeutics v. Liquidia (1:21-mc-22806): Litigation Summary, Patent-Scope Analysis, and Commercial Impact

Last updated: July 17, 2026

United Therapeutics Corporation (UTC) sued Liquidia Technologies, Inc. in a Delaware federal court matter designated 1:21-mc-22806. The proceeding is a multicase (MC) docket, which typically bundles related filings such as patent disputes tied to a specific FDA product and its regulatory filings. This litigation record impacts timing and entry strategy for competing therapies in the pulmonary arterial hypertension (PAH) inhalation space, where both companies’ portfolios intersect around inhaled delivery formats and formulation/process IP.

What is the status of United Therapeutics Corp v. Liquidia Technologies Inc, 1:21-mc-22806?

Status snapshot (MC docket): The case is identified as 1:21-mc-22806 and is associated with a multicase docket entry (MC). Without the underlying PACER docket events, orders, and complaint/response content, a complete procedural timeline (motions to dismiss, claim construction, injunction posture, settlement milestones, and disposition) cannot be accurately reconstructed from the docket identifier alone.

Why the MC label matters for legal strategy

An MC docket entry usually indicates:

• Multiple related filings can be managed under one umbrella docket.
• The “real” case may sit within an MDL-like organization or a consolidated procedural stream with shared issues, which affects:
  • Motion briefing timelines
  • Claim-construction coordination
  • Settlement leverage across related patents

What patents does United Therapeutics claim against Liquidia in 1:21-mc-22806?

Answer: The docket identifier 1:21-mc-22806 by itself does not specify:

• Asserted patent numbers
• Claim charts
• The drug product or formulation tied to the asserted claims
• Whether UTC asserted composition-of-matter, formulation, method-of-treatment, or manufacturing/process claims

Patent-scope analysis framework used in UTC v. inhaled delivery cases

UTC’s PAH litigation patterns (across multiple venues and counterpart defendants) often center on one or more of these categories:

• Inhalation device and formulation combinations (particle size, density, excipient system, and aerosolization behavior)
• Method-of-use dosing regimens (timing, titration, or patient subgroups)
• Manufacturing/process controls (mixing, granulation, spray-drying or particle engineering parameters)

A complete, claim-level analysis for this specific docket requires the complaint and the list of asserted patents.

When does exclusivity expire for the product at issue in UTC v. Liquidia?

Answer: Exclusivity timing (patent expiration and FDA exclusivity such as 5-year/7-year) depends on:

• The specific UTC product (active ingredient and dosage form)
• The competing Liquidia product (ANDA/NDA/BLA pathway or Section 505(b)(2) pathway)
• The Orange Book listing(s) and any relevant pediatric exclusivity extensions

The docket number alone does not establish:

• Which NDA/ANDA/BLA is at issue
• Whether the dispute is tied to Paragraph IV certification
• Whether a settlement triggered an “entry carve-out” by NDA/label trigger

What is the Orange Book status of the UTC-listed patents implicated by Liquidia’s filing?

Answer: Orange Book status cannot be tied to the docket number alone. A legal and commercial “Orange Book map” requires:

• The asserted NDA (or ANDA reference listed drug, RLD)
• The patent numbers appearing in the Orange Book for that RLD
• Expiration dates, exclusivity expiration, and listed use codes

How Orange Book mapping changes the litigation value

Patent type mapping determines:

• Whether the case is likely to turn on validity (anticipation/obviousness) or infringement (aerosol performance, dosing profile, or process steps)
• Whether Liquidia’s generic entry risk is centered on a narrow claim or broad enforceable coverage
• Settlement range assumptions (early launch vs. delayed launch)

Did Liquidia challenge the asserted patents via Paragraph IV (ANDA) or another FDA pathway?

Answer: The docket identifier 1:21-mc-22806 does not specify whether the FDA pathway is:

• ANDA with Paragraph IV (or Paragraph III) certifications
• 505(b)(2) litigation framework
• Biologic/Biosimilar context (BLA pathway)
• 351(a) or 351(k) pathway

Litigation posture that typically correlates with FDA certifications

Paragraph IV cases usually produce:

• A formal infringement-and-invalidation complaint
• An FDA-driven launch timing trigger tied to statutory stays
• Settlements that include “carve-out” dates matching cert-driven timelines

Without the FDA pathway and certification details, the entry risk cannot be analyzed with accuracy.

How strong is the patent estate for United Therapeutics versus Liquidia, based on litigation posture?

Answer: Strength cannot be scored without:

• The asserted claims and independent claim sets
• Claim construction outcomes
• Whether UTC sought and received preliminary injunction or TRO
• The standard applied by the court and the claim chart specifics

Typical strength indicators in UTC’s inhalation-related estates

Where UTC asserts formulation and delivery technology, strength often depends on:

• Whether the prior art teaches the specific particle engineering or aerosol characteristics
• Whether the claims are limited enough to avoid obviousness
• Whether dependent claims narrow infringement to the accused product’s measurable properties
• Whether manufacturing/process claims are supported with clear, reproducible parameters

What defenses has Liquidia raised in 1:21-mc-22806?

Answer: The docket identifier alone does not include the defense list. A defensibility analysis normally requires:

• Motion to dismiss grounds (indefiniteness, failure to state a claim, improper venue)
• Non-infringement theories (different formulation, different device integration, different dosing mechanism)
• Invalidity theories (anticipation, obviousness, lack of enablement, written description, indefiniteness)
• Unenforceability (inequitable conduct) or exhaustion if relevant

Did the parties reach a settlement, and what does it mean for generic entry timing?

Answer: Settlement terms and entry carve-outs cannot be derived from the docket number alone. Settlement value depends on:

• Whether there was a stipulated dismissal with or without prejudice
• Whether the parties agreed to a “trigger date” for launch
• Whether the settlement included non-monetary terms affecting product design (device, formulation, or manufacturing changes)
• Whether Liquidia agreed to redesign around specific claims

How does UTC v. Liquidia affect competitive landscape in inhaled PAH therapies?

Answer: Competitive impact depends on:

• Which products are involved
• Whether Liquidia’s entry is blocked by injunction or statutory stay
• The remaining life of the specific asserted patents and exclusivity

Inhaled PAH markets are sensitive to:

• FDA labeling and interchangeability
• Patient adherence and dosing cadence (which often ties to device/formulation IP)
• Payer reimbursement decisions contingent on launch and expected substitution

A product-specific analysis cannot be completed without the docket’s asserted product and related FDA records.

Case timeline and key litigation milestones (what to extract from the docket)

Required docket artifacts for accurate timelines:

• Complaint filing date
• List of asserted patents and counts
• Liquidia’s answer and counterclaims
• Court orders on claim construction, discovery, and motions
• Hearing dates for TRO/preliminary injunction (if any)
• Final disposition (dismissal, summary judgment, settlement, trial outcome)
• Any Federal Circuit appeal notices (if applicable)

Note: The docket number alone does not provide these milestones.

Key Takeaways

• The docket identifier 1:21-mc-22806 confirms a United Therapeutics v. Liquidia multicase matter, but it does not supply the patent list, procedural posture, or disposition necessary for an accurate infringement/validity and exclusivity analysis.
• Patent estate strength, Paragraph IV risk, and launch timing effects all require the asserted patent numbers, the FDA pathway, and the court’s rulings.
• A litigation-grade summary must be built from the complaint, Answer/Counterclaims, and dispositive orders or settlement papers tied to this MC docket.

FAQs

1. What is the difference between an MC docket and a standard civil case docket in federal patent litigation?
2. How do courts typically treat formulation and aerosol-performance claims in inhaled therapeutics patent disputes?
3. What factors determine whether a settlement delays generic launch by design-around rather than money?
4. How do claim construction outcomes usually shift leverage in patent infringement cases?
5. What Orange Book elements (patents vs exclusivity) most directly control FDA entry timing in Hatch-Waxman disputes?

References

1. United States District Court docket: 1:21-mc-22806 (United Therapeutics Corporation v. Liquidia Technologies, Inc.).